APEX-TRUTIDE

APEX-TRUTIDE is a synthetic acylated peptide designed as a triple incretin receptor agonist, engaging the glucagon-like peptide-1 (GLP-1) receptor, glucose-dependent insulinotropic polypeptide (GIP) receptor, and glucagon (GCG) receptor simultaneously. This tri-receptor activation profile distinguishes APEX-TRUTIDE from dual GLP-1/GIP agonists such as Tirzepatide, as the addition of glucagon receptor agonism introduces a third axis of metabolic modulation — specifically increasing energy expenditure and hepatic glucose production in a counterbalanced manner alongside the insulinotropic and anorectic effects of GLP-1 and GIP receptor co-activation. Researchers studying the physiological interplay between incretin and glucagon signaling axes utilize Retatrutide as a well-characterized probe for dissecting the relative contributions of each receptor system.

In preclinical and Phase 2 research models, APEX-TRUTIDE has been investigated for its effects on energy substrate partitioning, hepatic lipid metabolism, gastric emptying rate modulation, and postprandial glucose excursion. Published Phase 2 trial data (Jastreboff et al., NEJM 2023; Rosenstock et al., Lancet 2023) have characterized its pharmacokinetic profile and receptor engagement in human subjects, establishing a data foundation for ongoing mechanistic research. Its extended half-life, achieved through fatty acid acylation enabling albumin binding, supports once-weekly dosing paradigms in research settings. All applications referenced herein reflect investigational research contexts only; supplied as a lyophilized powder, reconstitute with sterile bacteriostatic water prior to use.